Disease modeling is an important field to understand in terms of human health for the present and the future. A disease model is an animal or cells displaying all or some of the pathological processes that are observed in the actual human or animal disease. Studying disease models aids understanding of how the disease develops and testing potential treatment approaches. We will take a look at how disease models are constructed currently and how bioprinting will help build disease models in the future.
One must know of some preliminary knowledge before we continue to discuss about bioprinting and disease modeling. Disease modeling utilizes different hosts to study underlying pathology of a disease. We can not experiment on a human due to moral and ethical grounds, so instead we typically use a mouse, rat, a pea plant, fish, nematodes, as well as fruit flies for our host site. We then inject said host with a particular disease and it allows us to study how the disease operates within that host. With disease models, we are able to use the information gathered from experimentation to figure out how we can prevent or reduce the spreading of different diseases within the human race.When animal models are employed in the study of human disease, they are frequently selected because of their similarity to humans in terms of genetics, anatomy, and physiology. Animal models are preferable for experimental disease research because of their unlimited supply and ease of manipulation. We can also utilize in vitro cell assays and inject these with different diseases. This allows us to study cell interaction as well.
With the methodology roughly outlined, we will now explain how bioprinting is important for this field. Conventional two-dimensional (2D) in vitro assays and animal models have been unable to fully recapitulate the critical characteristics of human physiology. Physiology refers to how organisms, organ systems, organs, cells, and biomolecules carry out the chemical and physical functions that exist in a living system. Alternatively, three-dimensional (3D) tissue models are often developed in a low-throughput manner and lack crucial native-like architecture. The recent emergence of bioprinting technologies has enabled creating 3D tissue models that address the critical challenges of conventional in vitro assays through the development of custom bioinks and patient derived cells coupled with well-defined arrangements of biomaterials.
Bioprinting is usefull because we can derive materials from human cells to see better reactions without needing to mutate an animal host to become similar to the human genome. There are a variety of diseases that humans contrive but are not within different organisms and their respective genomes. This causes one to necessitate mutation within a host. Ideally one would stay away from mutation when studying disease as that may be a variable that causes imperfect interpretation of results and studies of pathology. Also it is important to consider that physiology of a human is very different from the physiology of a rat, mouse, a plant, and etc. With bioprinting we can actually create scaffolds that have physiological properties similar to human tissue. That allows for more accurate studies as well of interaction from a physiology and pathology framework.
There still lies some areas of concern in terms of bioprinting and disease modeling. It is important for a bioprinted material used in disease modeling to have the following properties:
- Ability to survive for longer time periods
- Allows for safe cell proliferation
- Allows for safe cell differentiation
In order to study a disease pathology and physiology one needs to be able to trust that the material we are using will be able to last and live long enough for useful data or information collected from experimentation. There does not seem to be a lot of research done currently on degradation times of bioprinted tissue scaffolds. This level of uncertainty causes disease modeling to shy away from bioprinting currently. It is important to have clinical viability, and uncertainty is not needed in clinical settings.
Cell proliferation refers to the process that result in an increase of the number of cells, and is defined by the balance between cell divisions and cell loss through cell death or differentiation. This can be further understood through mitosis. Mitosis refers to a type of cell division that results in two daughter cells each having the same number and kind of chromosomes as the parent nucleus, typical of ordinary tissue growth. It is difficult at this stage to induce such cell proliferation within bioprinted materials. There are various studies that show proliferation within bioprinted materials, but there is not enough work done to be able to safely control proliferation.
Cellular differentiation is the process where a cell changes from one cell type to another. Usually, the cell changes to a more specialized type. Differentiation occurs numerous times during the development of a multicellular organism as it changes from a simple zygote to a complex system of tissues and cell types. Cellular differentiation must be controllable. The ability to tune bioprinting properties as an approach to fabricate stem cell bearing scaffolds and to also harness the benefits of the cells multipotency is of considerable relevance to the field of biomaterials and bioengineering. Without a regimented method to control differentiation within a disease modeling context, various things may go awry within experimentation.
Overall, disease modelling is ripe for change. With bioprinting, the future is intriguing and will be more accurate in term of studying human pathology and physiology of diseases because of us having the ability to derive tissue from patient derived cells. There are still a number of items that need to be changed in order for bioprinting within the disease modelling context to be used more thoroughly, and researchers are attempting to fix those issues.
This article is part of a series that wishes to make bioprinting more accessible. It starts with bioprinting 101, Hydrogels, 3D Industrial Bioprinters, Alginate, Bioinks, Pluronics, Applications, Gelatin, Decellularized Extracellular Matrices, and Tissue Engineering & Regenerative Medicine.
You May Also Like
Dream M&As: 3D Printing Mergers and Acquisitions We’d Like to See in 2021, Part 3
Inspired in part by the acquisition of EnvisionTEC by Desktop Metal, of 3D Hubs by ProtoLabs, and of Origin by Stratasys, we’ve been brainstorming about the newly hot 3D printing stocks and renewed interest...
3D Printing News Briefs, January 23, 2021: CADENAS, BCN3D, ExOne & AMGTA, 6K
We’ve got some business news for you in this weekend edition of 3D Printing News Briefs! CADENAS and BCN3D are both reporting good news from 2020, and ExOne has just...
CEO Meddah Hadjar to Leave SLM Solutions
SLM Solutions (AM3D.DE) has announced that its CEO, Meddah Hadjar, will not be extending his contract with the company at the end of January 2021. The company has stated the...
Dream M&As: 3D Printing Mergers and Acquisitions We’d Like to See in 2021, Part 2
Inspired in part by the acquisition of EnvisionTEC by Desktop Metal and of Origin by Stratasys, we’ve been brainstorming about the newly hot 3D printing stocks and renewed interest from investors in our markets. Is 2021 going...
View our broad assortment of in house and third party products.